Soligenix Inc. (NASDAQ: SNGX) has been featured in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, the demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte™ for cutaneous T-cell lymphoma (CTCL), now in its final confirmatory trial, positioning the company at the intersection of scientific innovation and evolving national health-policy priorities focused on chronic and rare conditions.
HyBryte (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy utilizing safe visible light for the treatment of CTCL. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The company is also expanding its synthetic hypericin program into psoriasis with SGX302, and advancing its first-in-class innate defense regulator technology, dusquetide (SGX942), for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 for Behçet’s Disease.
In its Public Health Solutions business segment, Soligenix is developing RiVax®, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax™ for the prevention of COVID-19. These programs incorporate the proprietary heat stabilization platform technology, ThermoVax®, and have been supported by government grants and contracts from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
The editorial underscores the critical need for innovative treatments as the population ages and the prevalence of rare diseases rises. Soligenix’s focus on rare disease therapies aligns with national health priorities, potentially offering new options for patients with limited or no approved treatments. For more information, view the full press release here.
